The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …

Janus kinase (JAK) inhibitors have become promising treatments for atopic dermatitis (AD),
however no study directly comparing JAK inhibitors with each other has been reported. We …

Background Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A
cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in …

Background Eczema (atopic dermatitis) is the most burdensome skin condition worldwide
and cannot currently be prevented or cured. Topical anti‐inflammatory treatments are used …

Atopic dermatitis represents a complex and multidimensional interaction that represents
potential fields of preventive and therapeutic management. In addition to the treatment …

Atopic dermatitis (AD) is a clinically heterogenous, inflammatory skin condition with a high
impact on patients' daily activities that remains difficult to treat. The knowledge acquired over …

Background Ruxolitinib cream demonstrated safety and efficacy over 8 weeks in 2 double-
blind phase 3 atopic dermatitis studies (NCT03745638/NCT03745651). Objective To …

Introduction The therapeutic efficacy of systemic Janus kinase (JAK) inhibitors in moderate-
to-severe atopic dermatitis (AD) is well established. However, the associated risk of incident …

Atopic dermatitis (AD) is the most common skin inflammatory disease. Dysregulation of
innate and adaptive immune systems plays a major role in the pathophysiology of AD. JAKi …

Introduction Atopic dermatitis is a common dermatologic condition that affects millions of
people worldwide, and a standardized approach to treatment was published by the …